Treating unwanted ocular condition using an ascomycin macrolactam
AssigneeAllergan, Inc.
InventorRhett M. Schiffman
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically active agent for the treatment of cancer.
Claims14
A method for treating an unwanted ocular condition occurring in a patient undergoing cancer treatment with a therapeutically active agent effective for treatment of a cancer, the method comprising the step of administering an effective amount of an ascomycin macrolactam to the patient, wherein the ascomycin macrolactam administration reduces a symptom of the ocular condition associated with the use of said therapeutically active agent effective for treatment of a cancer, wherein the ascomycin macrolactam is tacrolimus, pimecrolimus, ascomycin, or any combination thereof, and wherein the unwanted ocular condition is nasolacrimal stenosis, canalicular stenosis, lacrimal duct stenosis, chemotherapy induced ocular toxicity, lacrimation, abnormal lacrimation, epiphora, nasolacrimal blockage, dacryocystitis, or keratitis.
(canceled)
(canceled)
Dependencies are inferred from the claim text.